Mesa Laboratories (MLAB) investor relations material

Executive summary

• Revenue grew 1.0% year-over-year to $60.1 million for the quarter ended June 30, 2026, driven by gains in Calibration Solutions and Biopharmaceutical Development, offset by declines in Sterilization and Disinfection Control.

• Operating income rose 129% to $7.0 million, reflecting improved operating efficiencies and cost-containment initiatives.

• Net income declined 40.3% to $2.8 million, primarily due to higher non-operating expenses and a higher effective tax rate.

• Adjusted operating income (AOI) excluding unusual items increased 19.5% to $15.4 million, representing 25.6% of revenues.

• CEO's 100-day review identified delivery reliability as the main challenge, especially in the SDC segment.

Financial highlights

• Gross profit was $39.0 million (64.9% of revenues), up 5.6% year-over-year.

• Operating cash flow was $14.7 million, up from $1.9 million year-over-year.

• Diluted EPS was $0.49, down from $0.85 year-over-year.

• AOI per diluted share (non-GAAP) was $2.61; excluding unusual items, $2.68.

• Trailing 12-month AOI excluding unusual items was $66 million, up $2.5 million from fiscal 2026.

Outlook and guidance

• Full-year fiscal 2027 guidance will be provided at the next earnings call in November.

• Management expects continued focus on cost control, operating efficiency, and strategic investments to support future growth.

• First quarter trends are consistent with internal plans, and organic growth returned as expected.

• Focus remains on disciplined execution and capital allocation to high-return businesses.